USSTOCK.TODAY
Weekend. Closed Log in Sign up

Pasithea Therapeutics Corp(KTTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

KTTA
KTTA
Pasithea Therapeutics Corp
At close Nov 20 at 4:00 PM ET (Korea 11/21 06:00)
$0.48
+0.00 -0.48%
Nov 20 at 5:37 PM ET (Korea 11/21 07:37)
$0.47
-0.01 ▼ -2.92%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -1.37Insider Own ⓘ 3.59%Shs Outstand ⓘ 36.8MPerf Week ⓘ -8.3%
Market Cap ⓘ 0.02BForward P/E ⓘ -EPS next Y ⓘ 39.47%Insider Trans ⓘ 133.94%Shs Float ⓘ 35.4MPerf Month ⓘ 7.52%
Enterprise Value ⓘ -0.02BPEG ⓘ -EPS next Q ⓘ -0.21Inst Own ⓘ 55.91%Short Float ⓘ 1.09%Perf Quarter ⓘ -5.21%
Income ⓘ -0.02BP/S ⓘ -EPS this Y ⓘ 73.88%Inst Trans ⓘ -6.53%Short Ratio ⓘ 0.55Perf Half Y ⓘ -31.59%
Sales ⓘ 0.00BP/B ⓘ 0.37EPS next 5Y ⓘ 42.61%ROA ⓘ -82.61%Short Interest ⓘ 0.39MPerf YTD ⓘ -62.89%
Book/sh ⓘ 1.31P/C ⓘ 0.43EPS past 3/5Y ⓘ 35.92% -117.71%ROE ⓘ -88.78%52W High ⓘ -76.76% ($2.06)Perf Year ⓘ 15.32%
Cash/sh ⓘ 1.12P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -56.78%52W Low ⓘ 70.36% ($0.28)Perf 3Y ⓘ -92.55%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 73.07%Gross Margin ⓘ -Volatility(W/M) ⓘ 17.03% 17.82%Perf 5Y ⓘ -98.99%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.07Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 15.67EPS Q/Q ⓘ 51.75%Profit Margin ⓘ -RSI (14) ⓘ 49.5Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 15.67Sales Q/Q ⓘ -SMA20 ⓘ 0.23% ($0.48)Beta ⓘ 0.25Target Price ⓘ $4
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/09/02SMA50 ⓘ 1.48% ($0.47)Rel Volume ⓘ 0.14Prev Close ⓘ $0.48
Employees ⓘ 5LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ -SMA200 ⓘ -20.87% ($0.61)Avg Volume(3M) ⓘ 0.70MPrice ⓘ $0.48
IPO ⓘ 2021/9/15Option/Short ⓘ No/YesTrades ⓘ 169Volume ⓘ 100,725Change ⓘ -0.48%
Company
KTTA KTTAPasithea Therapeutics Corp | NASD | Biotechnology Deep dive

🧬 Pasithea Therapeutics () is a clinical-stage biotech developing PAS-004, a next-generation macrocyclic MEK inhibitor, as its lead pipeline candidate. The company primarily targets RASopathies and MAPK pathway-driven tumors, simultaneously running a Phase 1 trial for advanced solid tumors and a Phase 1/1b trial for plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1), while also securing FDA Fast Track designation.

Quote

Over the past 1 year, on the lower side

77% below its 1-year high.

Now $0.48
52w low$0.2852w high$2.06
52W Range11%
Volume ⓘ 100,725

Traded less than usual. That is 14% of its average volume.

B
Overall · fairly good
We judged 6 of the 8 questions below. 2 rate excellent and 2 need caution.
No data for valuation, dividends, or not applicable.
ETFs holding this stock 2 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #465 of 598 in the industry

Based on market cap of $18M.

FAQ

FAQ

KTTA belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of KTTA is approximately $18M, ranking 5,171 within its sector.

KTTA has recorded a 52-week high of $2.06 and a low of $0.28.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels